Trials / Completed
CompletedNCT04358224
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jonathan A. Bernstein, MD · Academic / Other
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis
Detailed description
The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/ skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels will be obtained at the beginning and end of treatment. Subjects will complete daily diaries assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each visit
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dupilumab Prefilled Syringe | open-label |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-11-18
- Completion
- 2022-11-18
- First posted
- 2020-04-24
- Last updated
- 2023-02-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04358224. Inclusion in this directory is not an endorsement.